Literature DB >> 1688245

Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.

W E Evans1, M V Relling.   

Abstract

Debrisoquine-hydroxylase (P450 2D6) not equal to phenotype was determined in 116 individuals using dextromethorphan as the substrate probe. Polymerase chain reaction and restriction fragment length polymorphism analyses were used to detect inactivating mutations in the CYP2D6 gene and assign genotype in all 116 individuals. Using a urinary metabolic ratio (DM/DT) of > or = 0.3 to define poor metabolizer (PM) phenotypes, 96 subjects were extensive metabolizers (EM) and 20 were PMs. The CYP2D6(B) mutation was the most common mutation, present in 18% of phenotypic EM alleles and 66% of the alleles in PM phenotypes. The CYP2D6(A) mutation (8% of PM alleles) and the CYP2D6 gene deletion (2.6% of PM alleles) were found less frequently. Seven different variants of the CYP2D6 gene were found. In subjects with two mutant alleles, genotype correctly predicted the PM phenotype in 100% (n = 13). Overall, genotype agreed with phenotype assignments in 109 of 116 (94%) subjects. Seven subjects with a wild-type allele at the CYP2D6(A) and CYP2D6(B) loci were phenotypic PMs, representing the only discrepant results. These discrepancies could be due to the imprecision of phenotype assignment or to as yet unknown mutations in CYP2D6. Although the median urinary metabolic ratio was significantly lower in homozygous EMs compared with heterozygous EMs, there was extensive overlap in metabolic ratios in these two groups, indicating that the DM/DT metabolic ratio cannot reliably discriminate homozygous EMs from heterozygous EMs.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1688245

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  10 in total

1.  Prediction of drug response and safety in clinical practice.

Authors:  Andrew A Monte; Kennon J Heard; Vasilis Vasiliou
Journal:  J Med Toxicol       Date:  2012-03

Review 2.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

Review 3.  Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping.

Authors:  D Frank; U Jaehde; U Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2007-02-02       Impact factor: 2.953

4.  Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects.

Authors:  Kyoung Soo Lim; Joo-Youn Cho; In-Jin Jang; Bo-Hyung Kim; JaeWoo Kim; Ji-Young Jeon; Yu-Mi Tae; SoJeong Yi; SoYoung Eum; Sang-Goo Shin; Kyung-Sang Yu
Journal:  Br J Clin Pharmacol       Date:  2008-07-24       Impact factor: 4.335

Review 5.  Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese.

Authors:  T Yokoi; T Kamataki
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

Review 6.  Pharmacogenetic phenotyping and genotyping. Present status and future potential.

Authors:  F J Gonzalez; J R Idle
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

7.  Ontogeny of Pediatric Pharmacogenetics: Celebrating the Past and Vision for the Future.

Authors:  J Steven Leeder
Journal:  J Pediatr Pharmacol Ther       Date:  2021-12-22

8.  Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics.

Authors:  Siew Hua Gan; Rusli Ismail; Wan Aasim Wan Adnan; Wan Zulmi
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

9.  Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans.

Authors:  W E Evans; M V Relling; A Rahman; H L McLeod; E P Scott; J S Lin
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

10.  An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution.

Authors:  A K Daly; J B Leathart; S J London; J R Idle
Journal:  Hum Genet       Date:  1995-03       Impact factor: 4.132

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.